Chemokine receptor binding heterocyclic compounds

A method to treat atherosclerosis comprises comprising administering to a subject in need of such treatment a compound of the formula

• V—CR2—Ar1—CR2NR—(CR2)x—Ar2
• wherein V is a heterocycle of 9–24 members containing 2–4 optionally substituted amine nitrogen atoms spaced from each other by 2 or more optionally substituted carbon atoms, and which heterocycle may optionally comprise a fused aromatic or heteroaromatic ring, and wherein
• (a) said heterocycle contains at least one O or S, said O or S spaced from any adjacent heteroatom by at least 2 carbon atoms, and wherein said S is optionally oxidized, or
• (b) the heterocycle contains 3 N and at least one carbon atom in said heterocycle is substituted by at least one fluoro substituent, or
• (c) both (a) and (b);
• and wherein each R is independently H or a straight chain, branched or cyclic alkyl containing 1–6C;
• x is 0–4;
• Ar1 is an unsubstituted or substituted aromatic or heteroaromatic moiety;
• and
• Ar2 is an unsubstituted or substituted aromatic or heterocyclic group;
• or
• the pharmaceutically acceptable salts and protected forms thereof.